Substrate reduction therapy
The glycosphingolipidoses are a family of storage diseases that arise due to incomplete catabolism of glycosphingolipids (GSLs) in the lysosome (Wraith, 2002). The majority are autosomal recessive disorders and result from mutations in the genes that encode the catabolic enzymes of the lysosome (Win...
Main Authors: | Platt, F, Butters, T |
---|---|
Formato: | Book section |
Publicado em: |
Springer US
2007
|
Registos relacionados
-
Substrate reduction therapy in mouse models of the glycosphingolipidoses.
Por: Platt, F, et al.
Publicado em: (2003) -
Substrate reduction therapy.
Por: Platt, F, et al.
Publicado em: (2008) -
Substrate reduction therapy for glycosphingolipid storage disorders.
Por: Lachmann, R, et al.
Publicado em: (2001) -
Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.
Por: Andersson, U, et al.
Publicado em: (2004) -
Substrate deprivation: a new therapeutic approach for the glycosphingolipid lysosomal storage diseases.
Por: Platt, F, et al.
Publicado em: (2000)